Topical tocoretinate improved hypertrophic scar, skin sclerosis in systemic sclerosis and morphea.

Abstract

Four patients with systemic scleroderma (SSc), 4 patients with morphea, and 4 patients with hypertrophic scar were treated with topical tocoretinate for 6 months to 3 years and studied clinically and histopathologically. Clinically, all of the lesions responded to this therapy. The stiffness of the skin lesions, glossy appearance of the lesions, and telangiectasia improved. Histopathologically, the proliferated collagen fibers decreased in thickness, and the inter-fiber spaces increased. Immunoreactive tenascin-C expressed in the proliferated deep dermal fibers of the SSc and hypertrophic scar lesions was markedly decreased compared with the level before the topical tocoretinate therapy. Topical tocoretinate has been used for the treatment of ulcers; it is also a potent treatment for sclerotic skin diseases.

• Authors: H Mizutani, T Yoshida, N Nouchi, H Hamanaka, M Shimizu
• Journal: The Journal of dermatology (J Dermatol) Vol. 26 Issue 1 Pg. 11-7 (Jan 1999) ISSN: 0385-2407 [Print] England
• PMID: 10063206 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Drug Combinations
• Vitamin E
• Tretinoin
• tocoretinate

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Child
• Child, Preschool
• Cicatrix, Hypertrophic (drug therapy, pathology)
• Drug Combinations
• Female
• Humans
• Middle Aged
• Scleroderma, Localized (drug therapy, pathology)
• Scleroderma, Systemic (drug therapy, pathology)
• Skin (pathology)
• Tretinoin (administration & dosage, analogs & derivatives)
• Vitamin E (administration & dosage, analogs & derivatives)